Tirzepatide: the complete guide
Tirzepatide is a synthetic dual incretin agonist activating both GIP and GLP-1 receptors. Clinical trials show weight loss and glycemic effects exceeding those of GLP-1-only agents.
How Tirzepatide works
Simultaneous agonism at GIP and GLP-1 receptors enhances insulin secretion, delays gastric emptying, and produces additive appetite suppression. GIP signaling may also improve lipid handling.
Typical Tirzepatide dosage
Commonly reported research ranges: Titration: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg weekly.
Dose should always be individualized. Factors that influence it include bodyweight, research goal, tolerance, and specific compound batch. The information below is educational, not a prescription.
How to reconstitute Tirzepatide
A widely used reconstitution for a 10 mg vial is 2 ml of bacteriostatic water. With a typical 2500 mcg dose this works out to the unit count shown in the calculator below.
Half-life and administration frequency
Approximately 5 days (once-weekly dosing).
This half-life informs how often Tirzepatide is typically dosed. Shorter half-lives usually mean more frequent dosing to maintain plasma levels; longer half-lives allow daily, weekly, or less-frequent administration depending on the compound.
Reported side effects
- Nausea (common, titration-dependent)
- GI upset
- Decreased appetite (often desired)
- Rare: pancreatitis, gallbladder disease
This list reflects effects reported in available literature or user logs. It is not exhaustive. Adverse reactions should be discussed with a qualified clinician.
Common Tirzepatide stacks
- Typically used alone
Full editorial stack guides featuring Tirzepatide:
Storage and handling
Lyophilized refrigerated preferred. Reconstituted: refrigerated 2–8 °C, use within 28 days.
FDA and regulatory status
FDA approved as Mounjaro (type 2 diabetes) and Zepbound (obesity). Compounded tirzepatide currently faces the same FDA scrutiny as semaglutide.
Tirzepatide clinical trials and evidence
For clinical-trial and primary-literature context, start with the sources below. We prioritize official drug labels, ClinicalTrials.gov records, and PubMed-indexed literature when available.
- SURPASS and SURMOUNT trial programs (ClinicalTrials.gov) — ClinicalTrials.gov
Track your Tirzepatide protocol on iPhone
Peptide Protocol logs every dose, calculates reconstitution for you, and keeps your full protocol on one calm screen.
See the app →Frequently asked questions
What is Tirzepatide?
Tirzepatide is a synthetic dual incretin agonist activating both GIP and GLP-1 receptors. Clinical trials show weight loss and glycemic effects exceeding those of GLP-1-only agents.
How does Tirzepatide work?
Simultaneous agonism at GIP and GLP-1 receptors enhances insulin secretion, delays gastric emptying, and produces additive appetite suppression. GIP signaling may also improve lipid handling.
What is a typical Tirzepatide dose?
Commonly reported ranges are Titration: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg weekly. This is research information, not a recommendation — dosing should be individualized under clinical guidance.
What is the half-life of Tirzepatide?
Approximately 5 days (once-weekly dosing). This influences how often it is administered.
How do you reconstitute Tirzepatide?
A common approach is to add 2 ml of bacteriostatic water to a 10 mg vial. Use the reconstitution calculator for exact unit counts.
What are the side effects of Tirzepatide?
Nausea (common, titration-dependent); GI upset; Decreased appetite (often desired); Rare: pancreatitis, gallbladder disease.
Is Tirzepatide FDA approved?
FDA approved as Mounjaro (type 2 diabetes) and Zepbound (obesity). Compounded tirzepatide currently faces the same FDA scrutiny as semaglutide.
Are there clinical trials for Tirzepatide?
Registered or published clinical-trial sources for Tirzepatide are listed in the references section below. Evidence depth varies widely by compound, so check the cited trial registries and primary literature before relying on any claim.
References
- Mounjaro / Zepbound prescribing information (FDA Drugs@FDA) — U.S. Food and Drug Administration. Official FDA-approved labeling for tirzepatide products
- SURPASS and SURMOUNT trial programs (ClinicalTrials.gov) — ClinicalTrials.gov. Phase 3 diabetes (SURPASS) and obesity (SURMOUNT) trial records
- Tirzepatide clinical literature (PubMed) — National Library of Medicine. Primary literature on dual GIP/GLP-1 agonism
Sources listed above were used to verify the claims on this page. See our editorial policy for how we source information.
Educational use only. Peptide Protocol is an informational tool. Nothing on this page constitutes medical advice. Many peptides are prescription-only or restricted in your jurisdiction. Always consult a licensed healthcare professional before injecting any compound.